04:53 AM EDT, 09/29/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Sunday their Alzheimer's therapy Leqembi has been approved for once every four weeks intravenous maintenance dosing by the National Medical Products Administration in China.

Leqembi was earlier approved for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of disease in China, the companies said.

After 18 months of a dosing regimen of 10 milligrams per kilogram once every two weeks during an initiation phase, a transition to a maintenance dosing regimen of 10 milligrams per kilogram once every four weeks may be considered, the companies said.

Eisai serves as the lead for drug's development and regulatory submissions worldwide while both companies are co-commercializing and co-promoting the product, they said.